Observed arrival · 2026-09-25
ImmuneStrata’s second-reading problem
An early-stage research company describes Sentira, an investigational approach to patch testing for allergic contact dermatitis.
○Open
⊠Login
$Paid
†Ads
✦Pretty
●Pro
◎Niche
◉Human
⚑Risk
ƒJS
- For
- Dermatologists, allergists, and clinical research collaborators
- Worth noticing
- The page labels its patch-test diagram as schematic, not ImmuneStrata data, and says no human studies of Sentira have been conducted.
Field notes
The page sets out the conventional workflow, including patches worn for about two days and readings that may continue across a week. It says the founders are physician-scientists working across allergy and immunology, dermatology, and bioengineering. The company lists a 2025–2026 research grant and a presentation at the American Contact Dermatitis Society's 2026 annual meeting; these are presented as company-reported credentials.
Observed signals
Read the marks
Editorial observations of this landing page, not a rating.
○OpenPublic substance visible
✦PrettyNotable craft visible
◎NicheUnusually specific use
◉HumanPersonal, local, civic, or handmade
One card from the complete issue